Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine
- Early clinical results show promising safety profile and partial responses in patients with neuroendocrine tumors and medullary thyroid carcinomas
- Fractionated doses of [212Pb]VMT-α-NET demonstrate effective tumor control in a mouse model of high-risk neuroblastoma
- None.
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM). The conference is being held in Vienna, Austria, from September 9-13, 2023.
“Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors. These results support our belief that targeted alpha therapies have the potential to revolutionize our approach to eliminating cancers and intractable tumors.”
“We are excited to have early results presented by Dr. Dharmender Malik of Fortis Memorial research institute on the safety and efficacy of 212Pb-VMT-α-NET especially in patients with somatostatin receptor positive, metastatic neuroendocrine and medullary thyroid tumors,” said Markus Puhlmann, MD, MBA, Chief Medical Officer at Perspective Therapeutics. “Additionally, we will present data from our metastatic mouse model of neuroblastoma exploring the efficacy of 203/212Pb-VMT-α-NET for image-guided treatment in this metastatic neuroblastoma tumor model.”
Details about these presentations can be found below and on the EANM website (eanm23.eanm.org). Additionally, copies of the abstracts can be found in the EANM ’23 Abstract Book on the EANM website.
Presentation One:
This presentation will discuss early clinical results from the study of 212Pb-VMT-α-NET in ten patients with somatostatin receptor (SSTR)-expressing progressive neuroendocrine tumors and metastatic medullary thyroid carcinomas. 212Pb-VMT-α-NET demonstrated an encouraging safety profile and treatment resulted in partial responses in a number of patients.
Title: Early results of 212Pb-VMT-α-NET Targeted Alpha Therapy in Metastatic Gastro-entero-pancreatic Neuroendocrine Tumors: First in Human Clinical Experience on Safety and Efficacy
Session: Theranostics Track – What’s New in Endocrine Tumors
Abstract Number: OP-673
Presenter: D. Malik, Consultant Nuclear Medicine and PET-CT, MBBS, DNB, FANMB & RSO-II at Fortis Memorial research institute (FMRI), Gurugram, India at Fortis Healthcare Pvt.
Details: Tuesday, September 12, 2023, 9:45 a.m. CEST
Location: Hall G1
Presentation Two:
This presentation will discuss the effective tumor control of fractionated doses of [212Pb]VMT-α-NET demonstrated in a mouse model of high-risk metastatic neuroblastoma. The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.
Title: Preclinical Evaluation of [212Pb]VMT-α-NET Targeted Alpha Therapy for High-Risk Metastatic Neuroblastoma
Session: M2M Track: Radioligand Therapy - New and Old Targets
Abstract Number: OP-144
Presenter: D. Liu, Principal Research Scientist, Perspective Therapeutics, Inc.
Details: Session 504, Sunday, September 10, 2023, 3.00 p.m. CEST
Location: Hall E2
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
The Company’s melanoma (VMT-01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations.
For more information, please visit the Company’s website at www.perspectivetherapeutics.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing thereof; the expected timing for availability and release of data; expectations regarding the potential market opportunities for the Company’s product candidates; the potential functionality, capabilities, and benefits of the Company’s product candidates; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company’s product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for the Company’s product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company’s ability to maintain its key employees; sufficient training and use of the Company’s products and product candidates; the market acceptance and recognition of the Company’s products and product candidates; the Company’s ability to maintain and enforce its intellectual property rights; the Company’s ability to maintain its therapeutic isotope supply agreement with the Department of Energy; the Company’s ability to continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Transition Report on Form 10-KT and the Company’s most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov.
Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
